Are you over 18 and want to see adult content?
More Annotations
A complete backup of https://visionabacus.com
Are you over 18 and want to see adult content?
A complete backup of https://yleisurheilu.fi
Are you over 18 and want to see adult content?
A complete backup of https://swedenoffroad.com
Are you over 18 and want to see adult content?
A complete backup of https://finanzfrage.net
Are you over 18 and want to see adult content?
A complete backup of https://easyliveauction.com
Are you over 18 and want to see adult content?
A complete backup of https://innerbonding.com
Are you over 18 and want to see adult content?
A complete backup of https://ninaberman.com
Are you over 18 and want to see adult content?
A complete backup of https://timekit.io
Are you over 18 and want to see adult content?
A complete backup of https://aedc.gov.au
Are you over 18 and want to see adult content?
A complete backup of https://mtbnmnm.com
Are you over 18 and want to see adult content?
A complete backup of https://matrixsynth.com
Are you over 18 and want to see adult content?
A complete backup of https://wtaps.com
Are you over 18 and want to see adult content?
Favourite Annotations
A complete backup of viasatinternet.es
Are you over 18 and want to see adult content?
A complete backup of willmarkhomes.co.uk
Are you over 18 and want to see adult content?
A complete backup of dreamteam2travel.com
Are you over 18 and want to see adult content?
A complete backup of tasksforsubsandslaves.tumblr.com
Are you over 18 and want to see adult content?
A complete backup of palmtreat.design
Are you over 18 and want to see adult content?
A complete backup of definitelysoul.de
Are you over 18 and want to see adult content?
A complete backup of historiaymisterios.com
Are you over 18 and want to see adult content?
A complete backup of fotografieuitdaging.nl
Are you over 18 and want to see adult content?
Text
SIGN IN
Sign In. Select the credentials you want to use to logon to this SharePoint site: Windows Authentication Forms Authentication ICRADFS. ICR login. Royal Marsden login. External login. ATARI - THE INSTITUTE OF CANCER RESEARCH, LONDON ATARI. ATARI: ATr inhibitor in combination with olaparib in gynaecological cancers with ARId1A loss or no loss Disease site: Relapsed gynaecological cancers Treatment modality: Systemic targeted therapy, ATR inhibitor, PARP inhibitor Status: Open to recruitment Trial details. ATARI is a multi-centre, open-label, multiple two-stage parallel cohorts phase II clinical trial for patients with BREAKTHROUGH GENERATIONS STUDY Breakthrough Generations Study. If you are interested in joining the study and would like us to send you further information, please enteryour details below:
POETIC-A - THE INSTITUTE OF CANCER RESEARCH, LONDON POETIC-A. Pre-Operative Endocrine Therapy for Individualised Care with Abemaciclib. Disease site: Breast cancer Treatment modality: Systemic therapy Status: Open to recruitment Trial details. POETIC-A is a phase III, multicentre trial that tests whether a new drug called abemaciclib, given in combination with standard endocrine therapy (ET), is more effective than giving ET alone. PROFESSOR UDAI BANERJI Professor Udai Banerji champions multidisciplinary working at the interface between early phase clinical trials, drug discovery and translational research related to drug resistance. He is a key member of the Cancer Therapeutics Unit, providing early clinical insights into areas of unmet need and clinical relevance during targetprioritisation.
PROFESSOR MANUEL SALTO-TELLEZ Professor Manuel Salto-Tellez is a recognised international leader in molecular and digital pathology. His research focus is on the relationship of phenotype to genotype, with a specific interest in the pathway of cancer biomarker development from discovery to clinicaladoption.
PROFESSOR NICOLA VALERI Professor Valeri is a Clinician/Scientist working to discover novel therapeutic targets and novel biomarkers for gastrointestinal cancers. He leads the Gastrointestinal Cancer Biology and Genomics Team within the Centre for Molecular Pathology at the ICR. Team: Gastrointestinal Cancer Biology and Genomics. +44 20 8722 4311 0000-0002-5426-5683.PROFESSOR VLAD PENA
Professor Vlad Pena uses biochemistry, electron cryo-microscopy and X-ray crystallography to understand splicing regulation and the connections between splicing and other gene expression processes. He is a Professor of Structural Biology and Gene Expression at the ICR. Team: Mechanisms and Regulation of pre-mRNA Splicing 0000-0002-7013-5504.DR BEN O'LEARY
Ben's current research is focused on understanding the evolution of resistance to cancer therapies in breast and head and neck cancers. In many patients with cancer it is possible to pick up traces of the cancer's DNA from a blood sample, known as 'circulating tumour DNA' or 'ctDNA'. Recently, the LIBRARY AND INFORMATION SERVICE The library and information service supports the academic and clinical work of The Institute of Cancer Research and the Royal Marsden NHS Foundation Trust. The library is based at our Sutton site and is open to visitors from outside the ICR. Visitors from academic institutions that are a member ofSIGN IN
Sign In. Select the credentials you want to use to logon to this SharePoint site: Windows Authentication Forms Authentication ICRADFS. ICR login. Royal Marsden login. External login. ATARI - THE INSTITUTE OF CANCER RESEARCH, LONDON ATARI. ATARI: ATr inhibitor in combination with olaparib in gynaecological cancers with ARId1A loss or no loss Disease site: Relapsed gynaecological cancers Treatment modality: Systemic targeted therapy, ATR inhibitor, PARP inhibitor Status: Open to recruitment Trial details. ATARI is a multi-centre, open-label, multiple two-stage parallel cohorts phase II clinical trial for patients with BREAKTHROUGH GENERATIONS STUDY Breakthrough Generations Study. If you are interested in joining the study and would like us to send you further information, please enteryour details below:
POETIC-A - THE INSTITUTE OF CANCER RESEARCH, LONDON POETIC-A. Pre-Operative Endocrine Therapy for Individualised Care with Abemaciclib. Disease site: Breast cancer Treatment modality: Systemic therapy Status: Open to recruitment Trial details. POETIC-A is a phase III, multicentre trial that tests whether a new drug called abemaciclib, given in combination with standard endocrine therapy (ET), is more effective than giving ET alone. PROFESSOR UDAI BANERJI Professor Udai Banerji champions multidisciplinary working at the interface between early phase clinical trials, drug discovery and translational research related to drug resistance. He is a key member of the Cancer Therapeutics Unit, providing early clinical insights into areas of unmet need and clinical relevance during targetprioritisation.
PROFESSOR MANUEL SALTO-TELLEZ Professor Manuel Salto-Tellez is a recognised international leader in molecular and digital pathology. His research focus is on the relationship of phenotype to genotype, with a specific interest in the pathway of cancer biomarker development from discovery to clinicaladoption.
PROFESSOR NICOLA VALERI Professor Valeri is a Clinician/Scientist working to discover novel therapeutic targets and novel biomarkers for gastrointestinal cancers. He leads the Gastrointestinal Cancer Biology and Genomics Team within the Centre for Molecular Pathology at the ICR. Team: Gastrointestinal Cancer Biology and Genomics. +44 20 8722 4311 0000-0002-5426-5683.PROFESSOR VLAD PENA
Professor Vlad Pena uses biochemistry, electron cryo-microscopy and X-ray crystallography to understand splicing regulation and the connections between splicing and other gene expression processes. He is a Professor of Structural Biology and Gene Expression at the ICR. Team: Mechanisms and Regulation of pre-mRNA Splicing 0000-0002-7013-5504.DR BEN O'LEARY
Ben's current research is focused on understanding the evolution of resistance to cancer therapies in breast and head and neck cancers. In many patients with cancer it is possible to pick up traces of the cancer's DNA from a blood sample, known as 'circulating tumour DNA' or 'ctDNA'. Recently, the LIBRARY AND INFORMATION SERVICE The library and information service supports the academic and clinical work of The Institute of Cancer Research and the Royal Marsden NHS Foundation Trust. The library is based at our Sutton site and is open to visitors from outside the ICR. Visitors from academic institutions that are a member ofSCIENCE TALK
Hilary Morgan kindly shared the story of her husband, Tim, to support our bowel cancer fundraising appeal. Tim was diagnosed with advanced bowel cancer at the age of 43. Here, Hilary tells us more about how pioneering treatments gave him a chance to LEADING ICR SCIENTISTS RECOGNISED BY THE ROYAL COLLEGE OF 8 hours ago · Image: Professor Nick James and Professor Emma Hall. Professor Nick James and Professor Emma Hall were recognised for their contributions to radiology and oncology by the Royal College of Radiologists in a virtual admission ceremony today.. Professor James was awarded the Royal College of Radiologists’ Gold Medal ‘in recognition of his enormous contribution to treatment of PROFESSOR UDAI BANERJI Professor Udai Banerji champions multidisciplinary working at the interface between early phase clinical trials, drug discovery and translational research related to drug resistance. He is a key member of the Cancer Therapeutics Unit, providing early clinical insights into areas of unmet need and clinical relevance during targetprioritisation.
ICR RESEARCHERS REVEAL HOW THEY ARE TACKLING RARE CANCERS For our latest Discovery Club, members met virtually with some of our leading scientists, who are using cutting-edge methods to assess and treat rare cancers such as sarcoma and other cancers of unmet need. During the evening, guests learned more about how they helping to find new treatment options for these patients who desperately need them - and why philanthropic support is so ICR ANNOUNCES NEW CHAIR OF BOARD OF TRUSTEES Professor Julia Buckingham CBE, an acclaimed medical researcher with exceptional leadership experience in academic institutions and across the sector, will become Chair of The Institute of Cancer Research, London, in August. Professor Buckingham is oneBOWEL CANCER APPEAL
Bowel cancer patients urgently need new treatment options. Your support today will help bring us one step closer to more effective immunotherapy treatments for bowel cancer - and give these patients the chance to finish what they started. Tim Morgan was diagnosed with advanced bowel cancer in 2015SCIENCE TALK
With our Science Talk blog, we hope to lift the lid on the black box that is the ICR: to show you inside our labs, to introduce you to a few of the people here who make the discoveries, and to allow them to tell some of the stories behind the science. We try to put our discoveries in a wider scientific context, and give an idea of how our science is actually done. NEW ‘SEARCH AND DESTROY’ TREATMENT EXTENDS LIFE IN A new high-tech drug treatment for prostate cancer, which delivers a precisely targeted dose of radiation to cancer cells, can keep patients alive and healthy for longer, a new phase III trial reports. The ‘search and destroy’ treatment could shrink tumours while leaving healthy cells unharmedSCIENCE TALK
The past weekend saw the return of one of the biggest yearly events in cancer research, the American Society of Clinical Oncology (ASCO) Annual Meeting.. Cancer researchers and clinicians, patients and the press from all over the world attended the virtual event, gathering together in online spaces to hear about the latest cutting-edge developments in the field. LIBRARY AND INFORMATION SERVICE The library and information service supports the academic and clinical work of The Institute of Cancer Research and the Royal Marsden NHS Foundation Trust. The library is based at our Sutton site and is open to visitors from outside the ICR. Visitors from academic institutions that are a member ofSIGN IN
Sign In. Select the credentials you want to use to logon to this SharePoint site: Windows Authentication Forms Authentication ICRADFS. ICR login. Royal Marsden login. External login. BREAKTHROUGH GENERATIONS STUDY Breakthrough Generations Study. If you are interested in joining the study and would like us to send you further information, please enteryour details below:
ATARI - THE INSTITUTE OF CANCER RESEARCH, LONDON ATARI. ATARI: ATr inhibitor in combination with olaparib in gynaecological cancers with ARId1A loss or no loss Disease site: Relapsed gynaecological cancers Treatment modality: Systemic targeted therapy, ATR inhibitor, PARP inhibitor Status: Open to recruitment Trial details. ATARI is a multi-centre, open-label, multiple two-stage parallel cohorts phase II clinical trial for patients with POETIC-A - THE INSTITUTE OF CANCER RESEARCH, LONDON POETIC-A. Pre-Operative Endocrine Therapy for Individualised Care with Abemaciclib. Disease site: Breast cancer Treatment modality: Systemic therapy Status: Open to recruitment Trial details. POETIC-A is a phase III, multicentre trial that tests whether a new drug called abemaciclib, given in combination with standard endocrine therapy (ET), is more effective than giving ET alone. PROFESSOR MANUEL SALTO-TELLEZ Professor Manuel Salto-Tellez is a recognised international leader in molecular and digital pathology. His research focus is on the relationship of phenotype to genotype, with a specific interest in the pathway of cancer biomarker development from discovery to clinicaladoption.
PROFESSOR NICOLA VALERI Professor Valeri is a Clinician/Scientist working to discover novel therapeutic targets and novel biomarkers for gastrointestinal cancers. He leads the Gastrointestinal Cancer Biology and Genomics Team within the Centre for Molecular Pathology at the ICR. Team: Gastrointestinal Cancer Biology and Genomics. +44 20 8722 4311 0000-0002-5426-5683. DR ANGURAJ SADANANDAM Sadanandam Lab website. Biography . Dr Sadanandam is a Team Leader (Associate Professor) at the Institute of Cancer Research (ICR), London since 2013 (tenured – 2018) and is currently applying his multidisciplinary skills to integrated science of systems biology to identify and test precise therapies for different subtypes of cancers using computational (artificial intelligencePROFESSOR VLAD PENA
Professor Vlad Pena uses biochemistry, electron cryo-microscopy and X-ray crystallography to understand splicing regulation and the connections between splicing and other gene expression processes. He is a Professor of Structural Biology and Gene Expression at the ICR. Team: Mechanisms and Regulation of pre-mRNA Splicing 0000-0002-7013-5504.PROBE MINER
Probe Miner
LIBRARY AND INFORMATION SERVICE The library and information service supports the academic and clinical work of The Institute of Cancer Research and the Royal Marsden NHS Foundation Trust. The library is based at our Sutton site and is open to visitors from outside the ICR. Visitors from academic institutions that are a member ofSIGN IN
Sign In. Select the credentials you want to use to logon to this SharePoint site: Windows Authentication Forms Authentication ICRADFS. ICR login. Royal Marsden login. External login. BREAKTHROUGH GENERATIONS STUDY Breakthrough Generations Study. If you are interested in joining the study and would like us to send you further information, please enteryour details below:
ATARI - THE INSTITUTE OF CANCER RESEARCH, LONDON ATARI. ATARI: ATr inhibitor in combination with olaparib in gynaecological cancers with ARId1A loss or no loss Disease site: Relapsed gynaecological cancers Treatment modality: Systemic targeted therapy, ATR inhibitor, PARP inhibitor Status: Open to recruitment Trial details. ATARI is a multi-centre, open-label, multiple two-stage parallel cohorts phase II clinical trial for patients with POETIC-A - THE INSTITUTE OF CANCER RESEARCH, LONDON POETIC-A. Pre-Operative Endocrine Therapy for Individualised Care with Abemaciclib. Disease site: Breast cancer Treatment modality: Systemic therapy Status: Open to recruitment Trial details. POETIC-A is a phase III, multicentre trial that tests whether a new drug called abemaciclib, given in combination with standard endocrine therapy (ET), is more effective than giving ET alone. PROFESSOR MANUEL SALTO-TELLEZ Professor Manuel Salto-Tellez is a recognised international leader in molecular and digital pathology. His research focus is on the relationship of phenotype to genotype, with a specific interest in the pathway of cancer biomarker development from discovery to clinicaladoption.
PROFESSOR NICOLA VALERI Professor Valeri is a Clinician/Scientist working to discover novel therapeutic targets and novel biomarkers for gastrointestinal cancers. He leads the Gastrointestinal Cancer Biology and Genomics Team within the Centre for Molecular Pathology at the ICR. Team: Gastrointestinal Cancer Biology and Genomics. +44 20 8722 4311 0000-0002-5426-5683. DR ANGURAJ SADANANDAM Sadanandam Lab website. Biography . Dr Sadanandam is a Team Leader (Associate Professor) at the Institute of Cancer Research (ICR), London since 2013 (tenured – 2018) and is currently applying his multidisciplinary skills to integrated science of systems biology to identify and test precise therapies for different subtypes of cancers using computational (artificial intelligencePROFESSOR VLAD PENA
Professor Vlad Pena uses biochemistry, electron cryo-microscopy and X-ray crystallography to understand splicing regulation and the connections between splicing and other gene expression processes. He is a Professor of Structural Biology and Gene Expression at the ICR. Team: Mechanisms and Regulation of pre-mRNA Splicing 0000-0002-7013-5504.PROBE MINER
Probe Miner
SCIENCE TALK
The past weekend saw the return of one of the biggest yearly events in cancer research, the American Society of Clinical Oncology (ASCO) Annual Meeting.. Cancer researchers and clinicians, patients and the press from all over the world attended the virtual event, gathering together in online spaces to hear about the latest cutting-edge developments in the field.SCIENCE TALK
ASCO 2021: The science behind olaparib’s promise shown in the OlympiA early breast cancer trial 03 Jun 2021. The OlympiA trial results show the benefits of a targeted drug in patients with early-stage breast cancer and inherited BRCA mutations. ICR RESEARCHERS REVEAL HOW THEY ARE TACKLING RARE CANCERS 15 hours ago · For our latest Discovery Club, members met virtually with some of our leading scientists, who are using cutting-edge methods to assess and treat rare cancers such as sarcoma and other cancers of unmet need. During the evening, guests learned more about how they helping to find new treatment options for these patients who desperately need them - and why philanthropic support is so ICR ANNOUNCES NEW CHAIR OF BOARD OF TRUSTEES Professor Julia Buckingham CBE, an acclaimed medical researcher with exceptional leadership experience in academic institutions and across the sector, will become Chair of The Institute of Cancer Research, London, in August. Professor Buckingham is onePROSTATE CANCER
Precision medicine. Precision medicine gives patients the best treatments according to the genetic profile of their cancer. One recent example of this is the drug olaparib, currently used to treat ovarian cancer, thanks to our scientists who played a major role in developing olaparib.. But further trials led by Professor Johann de Bono have shown that olaparib could also work in prostate TRIAL SHOWS BENEFITS OF TARGETED DRUG AGAINST EARLY-STAGE Image: Breast cancer cell. Credit: Anne Weston, Francis Crick Institute Women with high-risk, early-stage breast cancer who also have inherited faults in their BRCA1 or BRCA2 genes have shown a remarkable response to the targeted drug olaparib in a major clinical trial.. The OlympiA trial showed that adding olaparib for one year following standard treatment for patients who had an inheritedSIGN IN
Select the credentials you want to use to logon to this SharePointsite:
SCIENCE TALK
With our Science Talk blog, we hope to lift the lid on the black box that is the ICR: to show you inside our labs, to introduce you to a few of the people here who make the discoveries, and to allow them to tell some of the stories behind the science. We try to put our discoveries in a wider scientific context, and give an idea of how our science is actually done.IMPORT HIGH
IMPORT HIGH is a phase III, prospective, randomised controlled trial to test whether dose escalated, intensity-modulated radiotherapy after conservation surgery for early breast cancer could reduce radiotherapy side effects, whilst maintaining or increasing cancer cure, in women with higher than average local recurrence risk. NEW ‘SEARCH AND DESTROY’ TREATMENT EXTENDS LIFE IN A new high-tech drug treatment for prostate cancer, which delivers a precisely targeted dose of radiation to cancer cells, can keep patients alive and healthy for longer, a new phase III trial reports. The ‘search and destroy’ treatment could shrink tumours while leaving healthy cells unharmed THE INSTITUTE OF CANCER RESEARCH, LONDON ICR announces appointment of new Chief Executive. Professor Kristian Helin, a world-leading cancer researcher with exceptional leadership experience in three different countries, will become Chief Executive of the ICR in September. Read more . Scientists make ‘long-range weather forecasts’ of bowel cancer’s drug resistance. Scientistscan
LIBRARY AND INFORMATION SERVICE The library and information service supports the academic and clinical work of The Institute of Cancer Research and the Royal Marsden NHS Foundation Trust. The library is based at our Sutton site and is open to visitors from outside the ICR. Visitors from academic institutions that are a member ofSIGN IN
Sign In. Select the credentials you want to use to logon to this SharePoint site: Windows Authentication Forms Authentication ICRADFS. ICR login. Royal Marsden login. External login. PROFESSOR UDAI BANERJI Professor Udai Banerji champions multidisciplinary working at the interface between early phase clinical trials, drug discovery and translational research related to drug resistance. He is a key member of the Cancer Therapeutics Unit, providing early clinical insights into areas of unmet need and clinical relevance during targetprioritisation.
PROFESSOR NICOLA VALERI Professor Valeri is a Clinician/Scientist working to discover novel therapeutic targets and novel biomarkers for gastrointestinal cancers. He leads the Gastrointestinal Cancer Biology and Genomics Team within the Centre for Molecular Pathology at the ICR. Team: Gastrointestinal Cancer Biology and Genomics. +44 20 8722 4311 0000-0002-5426-5683. PROFESSOR JUDITH BLISS Professor Judith Bliss is investigating how best to personalise breast cancer treatment for individual patients. She is a member of several national and international research groups, and was recently appointed Vice-Chair of the UK Breast Intergroup. Team: ICR-CTSU Breast and Rare Cancers Trials. 0208 722 4297/4013 0000-0001-7957-7424.DR NAVITA SOMAIAH
Dr Navita Somaiah is a clinician scientist at The Institute of Cancer Research, London, and a clinical oncologist at The Royal Marsden. She is the first recipient of a prestigious Clinician Scientist Fellowship at the ICR. Team: Translational Breast Radiobiology 0000-0003-4609-0518.PROFESSOR VLAD PENA
Professor Vlad Pena uses biochemistry, electron cryo-microscopy and X-ray crystallography to understand splicing regulation and the connections between splicing and other gene expression processes. He is a Professor of Structural Biology and Gene Expression at the ICR. Team: Mechanisms and Regulation of pre-mRNA Splicing 0000-0002-7013-5504.PSSMSEARCH
PSSMSearch is a web application to discover novel protein motifs (SLiMs, mORFs, miniMotifs) and PTM sites. PSSMSearch analyses proteomes for regions with significant similarity to a specificity determinant model built from a set of aligned functional peptides. Query peptides can be provided by the users or retrieved from the ELMdatabase.
PROBE MINER
Probe Miner
THE INSTITUTE OF CANCER RESEARCH, LONDON ICR announces appointment of new Chief Executive. Professor Kristian Helin, a world-leading cancer researcher with exceptional leadership experience in three different countries, will become Chief Executive of the ICR in September. Read more . Scientists make ‘long-range weather forecasts’ of bowel cancer’s drug resistance. Scientistscan
LIBRARY AND INFORMATION SERVICE The library and information service supports the academic and clinical work of The Institute of Cancer Research and the Royal Marsden NHS Foundation Trust. The library is based at our Sutton site and is open to visitors from outside the ICR. Visitors from academic institutions that are a member ofSIGN IN
Sign In. Select the credentials you want to use to logon to this SharePoint site: Windows Authentication Forms Authentication ICRADFS. ICR login. Royal Marsden login. External login. PROFESSOR UDAI BANERJI Professor Udai Banerji champions multidisciplinary working at the interface between early phase clinical trials, drug discovery and translational research related to drug resistance. He is a key member of the Cancer Therapeutics Unit, providing early clinical insights into areas of unmet need and clinical relevance during targetprioritisation.
PROFESSOR NICOLA VALERI Professor Valeri is a Clinician/Scientist working to discover novel therapeutic targets and novel biomarkers for gastrointestinal cancers. He leads the Gastrointestinal Cancer Biology and Genomics Team within the Centre for Molecular Pathology at the ICR. Team: Gastrointestinal Cancer Biology and Genomics. +44 20 8722 4311 0000-0002-5426-5683. PROFESSOR JUDITH BLISS Professor Judith Bliss is investigating how best to personalise breast cancer treatment for individual patients. She is a member of several national and international research groups, and was recently appointed Vice-Chair of the UK Breast Intergroup. Team: ICR-CTSU Breast and Rare Cancers Trials. 0208 722 4297/4013 0000-0001-7957-7424.DR NAVITA SOMAIAH
Dr Navita Somaiah is a clinician scientist at The Institute of Cancer Research, London, and a clinical oncologist at The Royal Marsden. She is the first recipient of a prestigious Clinician Scientist Fellowship at the ICR. Team: Translational Breast Radiobiology 0000-0003-4609-0518.PROFESSOR VLAD PENA
Professor Vlad Pena uses biochemistry, electron cryo-microscopy and X-ray crystallography to understand splicing regulation and the connections between splicing and other gene expression processes. He is a Professor of Structural Biology and Gene Expression at the ICR. Team: Mechanisms and Regulation of pre-mRNA Splicing 0000-0002-7013-5504.PSSMSEARCH
PSSMSearch is a web application to discover novel protein motifs (SLiMs, mORFs, miniMotifs) and PTM sites. PSSMSearch analyses proteomes for regions with significant similarity to a specificity determinant model built from a set of aligned functional peptides. Query peptides can be provided by the users or retrieved from the ELMdatabase.
PROBE MINER
Probe Miner
SCIENCE TALK
The past weekend saw the return of one of the biggest yearly events in cancer research, the American Society of Clinical Oncology (ASCO) Annual Meeting.. Cancer researchers and clinicians, patients and the press from all over the world attended the virtual event, gathering together in online spaces to hear about the latest cutting-edge developments in the field.SCIENCE TALK
ASCO 2021: The science behind olaparib’s promise shown in the OlympiA early breast cancer trial 03 Jun 2021. The OlympiA trial results show the benefits of a targeted drug in patients with early-stage breast cancer and inherited BRCA mutations.HOW TO APPLY
PhD and MD(Res) – General applications. Prior to applying for a research degree at the ICR outside of the advertised funded programmes, candidates and their supervisors should discuss the appropriateness of the project and the candidates preference for either a PhD or an MD(Res). BREAKTHROUGH GENERATIONS STUDY Breakthrough Generations Study. If you are interested in joining the study and would like us to send you further information, please enteryour details below:
TRIAL SHOWS BENEFITS OF TARGETED DRUG AGAINST EARLY-STAGE Image: Breast cancer cell. Credit: Anne Weston, Francis Crick Institute Women with high-risk, early-stage breast cancer who also have inherited faults in their BRCA1 or BRCA2 genes have shown a remarkable response to the targeted drug olaparib in a major clinical trial.. The OlympiA trial showed that adding olaparib for one year following standard treatment for patients who had an inheritedSCIENCE TALK
With our Science Talk blog, we hope to lift the lid on the black box that is the ICR: to show you inside our labs, to introduce you to a few of the people here who make the discoveries, and to allow them to tell some of the stories behind the science. We try to put our discoveries in a wider scientific context, and give an idea of how our science is actually done.SIGN IN
Select the credentials you want to use to logon to this SharePointsite:
ICR ANNOUNCES NEW CHAIR OF BOARD OF TRUSTEES Professor Julia Buckingham CBE, an acclaimed medical researcher with exceptional leadership experience in academic institutions and across the sector, will become Chair of The Institute of Cancer Research, London, in August. Professor Buckingham is oneCAREER SUPPORT
The Institute of Cancer Research is committed to the best practice outlined in the Concordat to support the career development of researchers and has been awarded the HR excellence in research badge by the European Commission. Free careers advice, guidance and information is offered to all current NEW ‘SEARCH AND DESTROY’ TREATMENT EXTENDS LIFE IN A new high-tech drug treatment for prostate cancer, which delivers a precisely targeted dose of radiation to cancer cells, can keep patients alive and healthy for longer, a new phase III trial reports. The ‘search and destroy’ treatment could shrink tumours while leaving healthy cells unharmed THE INSTITUTE OF CANCER RESEARCH, LONDON ICR announces appointment of new Chief Executive. Professor Kristian Helin, a world-leading cancer researcher with exceptional leadership experience in three different countries, will become Chief Executive of the ICR in September. Read more . Scientists make ‘long-range weather forecasts’ of bowel cancer’s drug resistance. Scientistscan
LIBRARY AND INFORMATION SERVICE The library and information service supports the academic and clinical work of The Institute of Cancer Research and the Royal Marsden NHS Foundation Trust. The library is based at our Sutton site and is open to visitors from outside the ICR. Visitors from academic institutions that are a member ofSIGN IN
Sign In. Select the credentials you want to use to logon to this SharePoint site: Windows Authentication Forms Authentication ICRADFS. ICR login. Royal Marsden login. External login. PROFESSOR UDAI BANERJI Professor Udai Banerji champions multidisciplinary working at the interface between early phase clinical trials, drug discovery and translational research related to drug resistance. He is a key member of the Cancer Therapeutics Unit, providing early clinical insights into areas of unmet need and clinical relevance during targetprioritisation.
PROFESSOR NICOLA VALERI Professor Valeri is a Clinician/Scientist working to discover novel therapeutic targets and novel biomarkers for gastrointestinal cancers. He leads the Gastrointestinal Cancer Biology and Genomics Team within the Centre for Molecular Pathology at the ICR. Team: Gastrointestinal Cancer Biology and Genomics. +44 20 8722 4311 0000-0002-5426-5683. PROFESSOR JUDITH BLISS Professor Judith Bliss is investigating how best to personalise breast cancer treatment for individual patients. She is a member of several national and international research groups, and was recently appointed Vice-Chair of the UK Breast Intergroup. Team: ICR-CTSU Breast and Rare Cancers Trials. 0208 722 4297/4013 0000-0001-7957-7424.DR NAVITA SOMAIAH
Dr Navita Somaiah is a clinician scientist at The Institute of Cancer Research, London, and a clinical oncologist at The Royal Marsden. She is the first recipient of a prestigious Clinician Scientist Fellowship at the ICR. Team: Translational Breast Radiobiology 0000-0003-4609-0518.PROFESSOR VLAD PENA
Professor Vlad Pena uses biochemistry, electron cryo-microscopy and X-ray crystallography to understand splicing regulation and the connections between splicing and other gene expression processes. He is a Professor of Structural Biology and Gene Expression at the ICR. Team: Mechanisms and Regulation of pre-mRNA Splicing 0000-0002-7013-5504.PSSMSEARCH
PSSMSearch is a web application to discover novel protein motifs (SLiMs, mORFs, miniMotifs) and PTM sites. PSSMSearch analyses proteomes for regions with significant similarity to a specificity determinant model built from a set of aligned functional peptides. Query peptides can be provided by the users or retrieved from the ELMdatabase.
PROBE MINER
Probe Miner
THE INSTITUTE OF CANCER RESEARCH, LONDON ICR announces appointment of new Chief Executive. Professor Kristian Helin, a world-leading cancer researcher with exceptional leadership experience in three different countries, will become Chief Executive of the ICR in September. Read more . Scientists make ‘long-range weather forecasts’ of bowel cancer’s drug resistance. Scientistscan
LIBRARY AND INFORMATION SERVICE The library and information service supports the academic and clinical work of The Institute of Cancer Research and the Royal Marsden NHS Foundation Trust. The library is based at our Sutton site and is open to visitors from outside the ICR. Visitors from academic institutions that are a member ofSIGN IN
Sign In. Select the credentials you want to use to logon to this SharePoint site: Windows Authentication Forms Authentication ICRADFS. ICR login. Royal Marsden login. External login. PROFESSOR UDAI BANERJI Professor Udai Banerji champions multidisciplinary working at the interface between early phase clinical trials, drug discovery and translational research related to drug resistance. He is a key member of the Cancer Therapeutics Unit, providing early clinical insights into areas of unmet need and clinical relevance during targetprioritisation.
PROFESSOR NICOLA VALERI Professor Valeri is a Clinician/Scientist working to discover novel therapeutic targets and novel biomarkers for gastrointestinal cancers. He leads the Gastrointestinal Cancer Biology and Genomics Team within the Centre for Molecular Pathology at the ICR. Team: Gastrointestinal Cancer Biology and Genomics. +44 20 8722 4311 0000-0002-5426-5683. PROFESSOR JUDITH BLISS Professor Judith Bliss is investigating how best to personalise breast cancer treatment for individual patients. She is a member of several national and international research groups, and was recently appointed Vice-Chair of the UK Breast Intergroup. Team: ICR-CTSU Breast and Rare Cancers Trials. 0208 722 4297/4013 0000-0001-7957-7424.DR NAVITA SOMAIAH
Dr Navita Somaiah is a clinician scientist at The Institute of Cancer Research, London, and a clinical oncologist at The Royal Marsden. She is the first recipient of a prestigious Clinician Scientist Fellowship at the ICR. Team: Translational Breast Radiobiology 0000-0003-4609-0518.PROFESSOR VLAD PENA
Professor Vlad Pena uses biochemistry, electron cryo-microscopy and X-ray crystallography to understand splicing regulation and the connections between splicing and other gene expression processes. He is a Professor of Structural Biology and Gene Expression at the ICR. Team: Mechanisms and Regulation of pre-mRNA Splicing 0000-0002-7013-5504.PSSMSEARCH
PSSMSearch is a web application to discover novel protein motifs (SLiMs, mORFs, miniMotifs) and PTM sites. PSSMSearch analyses proteomes for regions with significant similarity to a specificity determinant model built from a set of aligned functional peptides. Query peptides can be provided by the users or retrieved from the ELMdatabase.
PROBE MINER
Probe Miner
SCIENCE TALK
The past weekend saw the return of one of the biggest yearly events in cancer research, the American Society of Clinical Oncology (ASCO) Annual Meeting.. Cancer researchers and clinicians, patients and the press from all over the world attended the virtual event, gathering together in online spaces to hear about the latest cutting-edge developments in the field.SCIENCE TALK
ASCO 2021: The science behind olaparib’s promise shown in the OlympiA early breast cancer trial 03 Jun 2021. The OlympiA trial results show the benefits of a targeted drug in patients with early-stage breast cancer and inherited BRCA mutations.HOW TO APPLY
PhD and MD(Res) – General applications. Prior to applying for a research degree at the ICR outside of the advertised funded programmes, candidates and their supervisors should discuss the appropriateness of the project and the candidates preference for either a PhD or an MD(Res). BREAKTHROUGH GENERATIONS STUDY Breakthrough Generations Study. If you are interested in joining the study and would like us to send you further information, please enteryour details below:
TRIAL SHOWS BENEFITS OF TARGETED DRUG AGAINST EARLY-STAGE Image: Breast cancer cell. Credit: Anne Weston, Francis Crick Institute Women with high-risk, early-stage breast cancer who also have inherited faults in their BRCA1 or BRCA2 genes have shown a remarkable response to the targeted drug olaparib in a major clinical trial.. The OlympiA trial showed that adding olaparib for one year following standard treatment for patients who had an inheritedSIGN IN
Select the credentials you want to use to logon to this SharePointsite:
ICR ANNOUNCES NEW CHAIR OF BOARD OF TRUSTEES Professor Julia Buckingham CBE, an acclaimed medical researcher with exceptional leadership experience in academic institutions and across the sector, will become Chair of The Institute of Cancer Research, London, in August. Professor Buckingham is oneSCIENCE TALK
With our Science Talk blog, we hope to lift the lid on the black box that is the ICR: to show you inside our labs, to introduce you to a few of the people here who make the discoveries, and to allow them to tell some of the stories behind the science. We try to put our discoveries in a wider scientific context, and give an idea of how our science is actually done.CAREER SUPPORT
The Institute of Cancer Research is committed to the best practice outlined in the Concordat to support the career development of researchers and has been awarded the HR excellence in research badge by the European Commission. Free careers advice, guidance and information is offered to all current NEW ‘SEARCH AND DESTROY’ TREATMENT EXTENDS LIFE IN A new high-tech drug treatment for prostate cancer, which delivers a precisely targeted dose of radiation to cancer cells, can keep patients alive and healthy for longer, a new phase III trial reports. The ‘search and destroy’ treatment could shrink tumours while leaving healthy cells unharmed THE INSTITUTE OF CANCER RESEARCH, LONDON ICR announces appointment of new Chief Executive. Professor Kristian Helin, a world-leading cancer researcher with exceptional leadership experience in three different countries, will become Chief Executive of the ICR in September. Read more . Scientists make ‘long-range weather forecasts’ of bowel cancer’s drug resistance. Scientistscan
LIBRARY AND INFORMATION SERVICE The library and information service supports the academic and clinical work of The Institute of Cancer Research and the Royal Marsden NHS Foundation Trust. The library is based at our Sutton site and is open to visitors from outside the ICR. Visitors from academic institutions that are a member of SIGN ININSTITUTE OF COST ACCOUNTANTS OF INDIANEXUS GOES SIGN INOX MAIL SIGN INNEXUSPAYABLES SIGN INOXFORD NEXUS SIGN INNEXUS MODS SIGN IN Sign In. Select the credentials you want to use to logon to this SharePoint site: Windows Authentication Forms Authentication ICRADFS. ICR login. Royal Marsden login. External login. PROFESSOR UDAI BANERJI Professor Udai Banerji champions multidisciplinary working at the interface between early phase clinical trials, drug discovery and translational research related to drug resistance. He is a key member of the Cancer Therapeutics Unit, providing early clinical insights into areas of unmet need and clinical relevance during targetprioritisation.
PROFESSOR NICOLA VALERI Professor Valeri is a Clinician/Scientist working to discover novel therapeutic targets and novel biomarkers for gastrointestinal cancers. He leads the Gastrointestinal Cancer Biology and Genomics Team within the Centre for Molecular Pathology at the ICR. Team: Gastrointestinal Cancer Biology and Genomics. +44 20 8722 4311 0000-0002-5426-5683. PROFESSOR JUDITH BLISS Professor Judith Bliss is investigating how best to personalise breast cancer treatment for individual patients. She is a member of several national and international research groups, and was recently appointed Vice-Chair of the UK Breast Intergroup. Team: ICR-CTSU Breast and Rare Cancers Trials. 0208 722 4297/4013 0000-0001-7957-7424.DR NAVITA SOMAIAH
Dr Navita Somaiah is a clinician scientist at The Institute of Cancer Research, London, and a clinical oncologist at The Royal Marsden. She is the first recipient of a prestigious Clinician Scientist Fellowship at the ICR. Team: Translational Breast Radiobiology 0000-0003-4609-0518.PROFESSOR VLAD PENA
Professor Vlad Pena uses biochemistry, electron cryo-microscopy and X-ray crystallography to understand splicing regulation and the connections between splicing and other gene expression processes. He is a Professor of Structural Biology and Gene Expression at the ICR. Team: Mechanisms and Regulation of pre-mRNA Splicing 0000-0002-7013-5504.PSSMSEARCH
PSSMSearch is a web application to discover novel protein motifs (SLiMs, mORFs, miniMotifs) and PTM sites. PSSMSearch analyses proteomes for regions with significant similarity to a specificity determinant model built from a set of aligned functional peptides. Query peptides can be provided by the users or retrieved from the ELMdatabase.
PROBE MINER
Probe Miner
THE INSTITUTE OF CANCER RESEARCH, LONDON ICR announces appointment of new Chief Executive. Professor Kristian Helin, a world-leading cancer researcher with exceptional leadership experience in three different countries, will become Chief Executive of the ICR in September. Read more . Scientists make ‘long-range weather forecasts’ of bowel cancer’s drug resistance. Scientistscan
LIBRARY AND INFORMATION SERVICE The library and information service supports the academic and clinical work of The Institute of Cancer Research and the Royal Marsden NHS Foundation Trust. The library is based at our Sutton site and is open to visitors from outside the ICR. Visitors from academic institutions that are a member of SIGN ININSTITUTE OF COST ACCOUNTANTS OF INDIANEXUS GOES SIGN INOX MAIL SIGN INNEXUSPAYABLES SIGN INOXFORD NEXUS SIGN INNEXUS MODS SIGN IN Sign In. Select the credentials you want to use to logon to this SharePoint site: Windows Authentication Forms Authentication ICRADFS. ICR login. Royal Marsden login. External login. PROFESSOR UDAI BANERJI Professor Udai Banerji champions multidisciplinary working at the interface between early phase clinical trials, drug discovery and translational research related to drug resistance. He is a key member of the Cancer Therapeutics Unit, providing early clinical insights into areas of unmet need and clinical relevance during targetprioritisation.
PROFESSOR NICOLA VALERI Professor Valeri is a Clinician/Scientist working to discover novel therapeutic targets and novel biomarkers for gastrointestinal cancers. He leads the Gastrointestinal Cancer Biology and Genomics Team within the Centre for Molecular Pathology at the ICR. Team: Gastrointestinal Cancer Biology and Genomics. +44 20 8722 4311 0000-0002-5426-5683. PROFESSOR JUDITH BLISS Professor Judith Bliss is investigating how best to personalise breast cancer treatment for individual patients. She is a member of several national and international research groups, and was recently appointed Vice-Chair of the UK Breast Intergroup. Team: ICR-CTSU Breast and Rare Cancers Trials. 0208 722 4297/4013 0000-0001-7957-7424.DR NAVITA SOMAIAH
Dr Navita Somaiah is a clinician scientist at The Institute of Cancer Research, London, and a clinical oncologist at The Royal Marsden. She is the first recipient of a prestigious Clinician Scientist Fellowship at the ICR. Team: Translational Breast Radiobiology 0000-0003-4609-0518.PROFESSOR VLAD PENA
Professor Vlad Pena uses biochemistry, electron cryo-microscopy and X-ray crystallography to understand splicing regulation and the connections between splicing and other gene expression processes. He is a Professor of Structural Biology and Gene Expression at the ICR. Team: Mechanisms and Regulation of pre-mRNA Splicing 0000-0002-7013-5504.PSSMSEARCH
PSSMSearch is a web application to discover novel protein motifs (SLiMs, mORFs, miniMotifs) and PTM sites. PSSMSearch analyses proteomes for regions with significant similarity to a specificity determinant model built from a set of aligned functional peptides. Query peptides can be provided by the users or retrieved from the ELMdatabase.
PROBE MINER
Probe Miner
SCIENCE TALK
ASCO 2021: The science behind olaparib’s promise shown in the OlympiA early breast cancer trial 03 Jun 2021. The OlympiA trial results show the benefits of a targeted drug in patients with early-stage breast cancer and inherited BRCA mutations.SCIENCE TALK
ASCO 2021: Global cancer researchers reunite virtually 02 Jun 2021. We look ahead at some of the highlights that scientists from The Institute of Cancer Research will be presenting at this year’s virtual edition of the ASCO Annual Meeting.HOW TO APPLY
PhD and MD(Res) – General applications. Prior to applying for a research degree at the ICR outside of the advertised funded programmes, candidates and their supervisors should discuss the appropriateness of the project and the candidates preference for either a PhD or an MD(Res). BREAKTHROUGH GENERATIONS STUDY Breakthrough Generations Study. If you are interested in joining the study and would like us to send you further information, please enteryour details below:
SIGN IN
Select the credentials you want to use to logon to this SharePointsite:
NEW ‘SEARCH AND DESTROY’ TREATMENT EXTENDS LIFE IN A new high-tech drug treatment for prostate cancer, which delivers a precisely targeted dose of radiation to cancer cells, can keep patients alive and healthy for longer, a new phase III trial reports. The ‘search and destroy’ treatment could shrink tumours while leaving healthy cells unharmed TRIAL SHOWS BENEFITS OF TARGETED DRUG AGAINST EARLY-STAGE Image: Breast cancer cell. Credit: Anne Weston, Francis Crick Institute Women with high-risk, early-stage breast cancer who also have inherited faults in their BRCA1 or BRCA2 genes have shown a remarkable response to the targeted drug olaparib in a major clinical trial.. The OlympiA trial showed that adding olaparib for one year following standard treatment for patients who had an inherited ICR ANNOUNCES NEW CHAIR OF BOARD OF TRUSTEES Professor Julia Buckingham CBE, an acclaimed medical researcher with exceptional leadership experience in academic institutions and across the sector, will become Chair of The Institute of Cancer Research, London, in August. Professor Buckingham is oneCAREER SUPPORT
The Institute of Cancer Research is committed to the best practice outlined in the Concordat to support the career development of researchers and has been awarded the HR excellence in research badge by the European Commission. Free careers advice, guidance and information is offered to all current STUDY POLYPHARMACOLOGY EARLIER IN DRUG DISCOVERY, SAY Polypharmacology – the ability of a drug to affect more than one protein – should be studied early in the drug discovery pathway, and constantly monitored as the chemical structure is optimised in the design of the clinical candidate, leading researchers believe. Skip to content Skip to main navigationMain Menu
* Our Research
* Our Research
* Research divisions * Breast Cancer Research* Cancer Biology
* Cancer Therapeutics* Clinical Studies
* Genetics and Epidemiology * Molecular Pathology * Radiotherapy and Imaging * Structural Biology * Researchers and teams * About our research * Our research strategy * Our research excellence* Childhood cancer
* Animal research at the ICR * Centres and collaborations * Centres at the ICR * The Royal Marsden partnerships * Strategic collaborations * Our strategic partners * Publications repository * Scientific services * Scientific resources * Studying and Training * Studying and Training * PhDs for science graduates * PhD studentships - July 2019 * ICR and Imperial Convergence Science PhD programme * Contact us and FAQs * Opportunities for clinicians* MSc in Oncology
* PhD and MD(Res) for clinicians * NIHR academic training * Radiotherapy and imaging training courses* Postgraduate life
* Sites and facilities* Student benefits
* Information for international students * Accommodation and transport* Student committee
* Student profiles
* Careers and destinations* Alumni profiles
* Resources and support* Tuition fees
* Education policies and strategies* E-learning
* Training and development * Library and information service* Career support
* Welfare and disability support* Student charter
* Resources for current students * Undergraduate Vacation Scholarship Scheme* Careers
* Careers
* Working at the ICR* Staff development
* Staff benefits
* Equality policies
* Our sites and facilities * Overseas applicants* Current vacancies
* Team Leader vacancies * Types of opportunities * Early-career researchers * Career development faculty* Career faculty
* Opportunities for clinicians* Employee profiles
* Working with Industry * Working with Industry * About the Enterprise Unit * Our philosophy for working with industry * Business Development * Clinical Trials Contracts* Working with us
* Opportunities
* Our researchers
* Our successes
* Our industrial collaborators* Case studies
* Contact the Enterprise Unit * Connections newsletter* Support Us
* Support Us
* Our appeals
* DNA appeal
* Childhood leukaemia * Immunotherapy appeal* Philanthropy
* Centre for Cancer Drug Discovery appeal * The Discovery Club * Cancer's last note* Special events
* Get involved
* Sports and challenges * Fundraise for the ICR * Join the #teamICR community * Cheering team volunteers * Meet our supporters* Donor stories
* Legacy supporters
* Supporter stories
* Family charity partners* Leave a legacy
* Will for free
* Giving in memory
* Our newsletter Search * Contact the Development Office* Make a donation
* About Us
* About Us
* ICR strategy
* Our research strategy * Learning and teaching strategy* Our values
* Our achievements
* Our scientific discoveries * Our academic excellence * Our commercialisation successes * Our annual research highlights* Our history
* How we are funded
* Annual reports
* Income and expenditure * How we are structured * Our leadership team* Board of Trustees
* Executive Board
* ICR committees
* Corporate governance * Position statements* Factsheets
* Responsibility
* Public engagement
Search
* News
* Blogs
* Videos
* Contacts
Instagram RSS
Search
Instagram RSS
* News
* Blogs
* Videos
* Contacts
Navigation
Advanced search
Making the discoveries that defeat cancer Donate now * Our Research
* Our Research
* Research divisions * Breast Cancer Research* Cancer Biology
* Cancer Therapeutics* Clinical Studies
* Genetics and Epidemiology * Molecular Pathology * Radiotherapy and Imaging * Structural Biology * Researchers and teams * About our research * Our research strategy * Our research excellence* Childhood cancer
* Animal research at the ICR * Centres and collaborations * Centres at the ICR * The Royal Marsden partnerships * Strategic collaborations * Our strategic partners * Publications repository * Scientific services * Scientific resources * Studying and Training * Studying and Training * PhDs for science graduates * PhD studentships - July 2019 * ICR and Imperial Convergence Science PhD programme * Contact us and FAQs * Opportunities for clinicians* MSc in Oncology
* PhD and MD(Res) for clinicians * NIHR academic training * Radiotherapy and imaging training courses* Postgraduate life
* Sites and facilities* Student benefits
* Information for international students * Accommodation and transport* Student committee
* Student profiles
* Careers and destinations* Alumni profiles
* Resources and support* Tuition fees
* Education policies and strategies* E-learning
* Training and development * Library and information service* Career support
* Welfare and disability support* Student charter
* Resources for current students * Undergraduate Vacation Scholarship Scheme* Careers
* Careers
* Working at the ICR* Staff development
* Staff benefits
* Equality policies
* Our sites and facilities * Overseas applicants* Current vacancies
* Team Leader vacancies * Types of opportunities * Early-career researchers * Career development faculty* Career faculty
* Opportunities for clinicians* Employee profiles
* Working with Industry * Working with Industry * About the Enterprise Unit * Our philosophy for working with industry * Business Development * Clinical Trials Contracts* Working with us
* Opportunities
* Our researchers
* Our successes
* Our industrial collaborators* Case studies
* Contact the Enterprise Unit * Connections newsletter* Support Us
* Support Us
* Our appeals
* DNA appeal
* Childhood leukaemia * Immunotherapy appeal* Philanthropy
* Centre for Cancer Drug Discovery appeal * The Discovery Club * Cancer's last note* Special events
* Get involved
* Sports and challenges * Fundraise for the ICR * Join the #teamICR community * Cheering team volunteers * Meet our supporters* Donor stories
* Legacy supporters
* Supporter stories
* Family charity partners* Leave a legacy
* Will for free
* Giving in memory
* Our newsletter Search * Contact the Development Office* Make a donation
* About Us
* About Us
* ICR strategy
* Our research strategy * Learning and teaching strategy* Our values
* Our achievements
* Our scientific discoveries * Our academic excellence * Our commercialisation successes * Our annual research highlights* Our history
* How we are funded
* Annual reports
* Income and expenditure * How we are structured * Our leadership team* Board of Trustees
* Executive Board
* ICR committees
* Corporate governance * Position statements* Factsheets
* Responsibility
* Public engagement
The Institute of Cancer Research, London, is one of the world’s most influential cancer research organisations. Find out about Teaching Week 2019 , read about our new Centre for Cancer Drug Discoveryor
sign up for our new research newsletter.
Back to top
*
POSITIVE CLINICAL TRIAL RESULTS FOR OLAPARIB IN ADVANCED PROSTATECANCER
The preliminary results of a major phase III clinical trial show that the genetically targeted drug olaparib improves outcomes for men with advanced prostate cancer whose tumours have DNA repair faults.Read more
*
LET’S FINISH IT: CENTRE FOR CANCER DRUG DISCOVERY APPEAL We are creating a new state-of-the art drug discovery centre to create more and better drugs for cancer patients. The centre is a £75m build – and we now have less than £15m to raise. To make our building a reality, we urgently need your philanthropic support.Support us
*
UK SCIENCE NEEDS A CLEAR PLAN FOR THE FUTURE If science in the UK is going to remain world class, it’s crucial that we have a clear plan for the future that secures research funding, ensures freedom for scientists to work across borders, and provides regulatory alignment, argues the ICR’s Chief Executive Professor Paul Workman.Read more
*
TUMOUR-LIQUIFYING MICROBUBBLES AND IMMUNE CELL TRACKING: UK’S FIRST CONVERGENCE SCIENCE CENTRE OFFICIALLY LAUNCHES The ICR and Imperial College London are coming together with funding from Cancer Research UK to launch the new £13 million ConvergenceScience Centre.
Read more
*
CELEBRATORY SYMPOSIUM FOR PROFESSOR MEL GREAVES A celebratory symposium at the Royal Society on 16 September will bring together distinguished leaders across the field of leukaemia research and treatment to celebrate Professor Sir Mel Greaves and his knighthood for his services to children's leukaemia research. Register for symposium 1/5
* Previous
* Next
*
CREATING NEW TREATMENTS THAT TARGET TUMOURS Teams of biologists, chemists and computational scientists design new drugs to selectively attack tumoursFind out more
*
INNOVATIVE APPROACHES We will take on the challenge of cancer’s complexity, evolution and drug resistance through the discovery of innovative new approaches tocancer treatment.
Find out more
*
MAKING IT COUNT
We will deliver better outcomes and improved quality of life for patients by establishing innovative treatments, diagnostics and strategies for prevention as part of routine healthcare.Find out more
*
SMARTER, KINDER TREATMENTS We will move a step closer to cure by bringing personalised treatments into the clinic and developing them for patients.Find out more
*
UNRAVELLING CANCER’S COMPLEXITY We will comprehend the full complexity of cancer by harnessing the power of new technologies and Big Data.Find out more
*
WINNER OF QUEEN'S ANNIVERSARY PRIZE The ICR has been recognised with a highly prestigious Queen’s Anniversary Prize for its world-leading research in cancer drugdiscovery.
Read more
Centre for Cancer Drug Discovery We are building a new state-of-the art drug discovery centre to create more and better drugs for cancer patients. To make our building a reality, we urgently need your philanthropic support.Find out more
Our scientific discoveries For more than 100 years, the ICR has played an important role in shaping understanding of cancer and how it can be treated.Find out more
Philanthropy
Philanthropy has played a key role in the progress we have made over the years and there are many opportunities to play a part in the future of cancer research.Find out more
The Drug Discoverer Our Chief Executive and President, Professor Paul Workman, shares his experiences on his blog, The Drug Discoverer.Find out more
Share your story
We always want to hear from people who have a cancer story to share. Get in touch and help raise awareness of our research.Find out more
How we work with industry We work in close partnership with industry to take results into the clinic as soon as possible, and make sure our research delivers forcancer patients.
Find out more
I'M LOOKING FOR
A researcher A job A fundraising event A PhD project
A commercial opportunity
LATEST NEWS
07 Aug
POSITIVE CLINICAL TRIAL RESULTS FOR OLAPARIB IN ADVANCED PROSTATECANCER
02 Aug
ARTIFICIAL INTELLIGENCE REVEALS NEW BREAST CANCER TYPES THAT RESPOND DIFFERENTLY TO TREATMENT01 Aug
PERSONALISED ‘LIQUID BIOPSY’ COULD DETECT RETURN OF BREAST CANCER NEARLY ELEVEN MONTHS EARLIER THAN HOSPITAL SCANSSee all news
FROM OUR BLOGS
TALES FROM THE LAB
05 AUGUST
Science Writing Prize 2019 - Sleep and cancerTALES FROM THE LAB
30 JULY
Science Writing Prize 2019 – Therapies galore, yet cancer hasn’t acure?
See all blogs
The ICR
@ICR_London
@sinead_cb Thank you for your support and good luck with your training! 👏Posted 1 hour ago
* Reply
* Retweet
* Like
The latest HubNews newsletter was sent out this week, collecting together all of the latest news and updates from T… https://t.co/J8z2l8rEnPPosted 10 hours ago
* Reply
* Retweet
* Like
Meet our key researchers who will be working in our #CentreforCancerDrugDiscovery:
https://t.co/bC8T1779SK They ar… https://t.co/mwLZQzbweKPosted 14 hours ago
* Reply
* Retweet
* Like
Follow us
LATEST VIDEOS
23 July
GENE PICKS OUT PROSTATE CANCERS PATIENTS WHO COULD BENEFIT FROM ‘SEARCH-AND-DESTROY’ MEDICINESee all videos
* Our Research
* Research divisions * Researchers and teams * About our research * Centres and collaborations * Our strategic partners * Publications repository * Scientific services * Scientific resources * Studying and Training * PhDs for science graduates * Opportunities for clinicians* Postgraduate life
* Learning and teaching strategy * Resources and support * Contact the Registry * Undergraduate Vacation Scholarship Scheme* Careers
* Working at the ICR* Current vacancies
* Types of opportunities * Opportunities for clinicians* Employee profiles
* Research division contacts * Working with Industry * About the Enterprise Unit* Working with us
* Our successes
* Contact the Enterprise Unit * Partnering to defeat cancer event* Support Us
* Our appeals
* Philanthropy
* Get involved
* Meet our supporters* Leave a legacy
* Our newsletter Search * Contact the Development Office* Make a donation
* Cancer discoveries* About Us
* ICR strategy
* Our achievements
* Our history
* How we are funded
* How we are structured * Corporate governance * Cancer Drug Access report * Cancer Drug Manifesto * Position statements* Factsheets
* Responsibility
* Public engagement
* Share your story
Instagram RSS
* Contacts
* Terms and conditions* Privacy
* Fundraising privacy statement * Modern slavery statement * 2018 Gender pay gap factsheet * Annual Renumeration statement* Cookies
* Accessibility
* Site map
Back to top
Copyright © 2019 The Institute of Cancer Research. All rightsreserved.
Registered office: The Institute of Cancer Research, 123 Old Brompton Road, London, SW7 3RP A Charity, Not for Profit. Company Limited by Guarantee. Registered in England No. 534147. VAT Registration No. GB 849 0581 02.Details
Copyright © 2024 ArchiveBay.com. All rights reserved. Terms of Use | Privacy Policy | DMCA | 2021 | Feedback | Advertising | RSS 2.0